Request Demo
Last update 20 Mar 2025
AK-001
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms |
Target |
Action inhibitors, modulators |
Mechanism Siglec-8 inhibitors(Sialic acid-binding Ig-like lectin 8 inhibitors), Immunomodulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 1116885928H
Sequence Code 9910317L
Related
2
Clinical Trials associated with AK-001NCT02734849
A Phase 2, Randomized, Double-blind, Placebo-controlled, Study to Evaluate Multiple Doses of AK001 in Patients With Moderate to Severe Nasal Polyposis
NCT02563938
A Phase 1, Randomized, Double-Blind, Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001 in Subjects With Atopic Disease
100 Clinical Results associated with AK-001
Login to view more data
100 Translational Medicine associated with AK-001
Login to view more data
100 Patents (Medical) associated with AK-001
Login to view more data
100 Deals associated with AK-001
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Nasal Polyps | Phase 2 | Belgium | 01 Apr 2016 | |
| Nasal Polyps | Phase 2 | Netherlands | 01 Apr 2016 | |
| Nasal Polyps | Phase 2 | Spain | 01 Apr 2016 | |
| Nasal Polyps | Phase 2 | United States | 01 Apr 2016 | |
| Nasal Polyps | Phase 2 | United Kingdom | 01 Apr 2016 | |
| Nasal Polyps | Phase 2 | Germany | 01 Apr 2016 | |
| Dermatitis, Atopic | Phase 2 | United States | 01 Sep 2015 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 40 | (25 mg AK001) | lsklhvipbp(uifjkbbvvu) = utipcaplzi hmzehcwluk (qnyrnrbvur, dvitshstsx - mjioaevyva) View more | - | 28 Dec 2020 | ||
(250 mg AK001) | lsklhvipbp(uifjkbbvvu) = nwfbcljhpl hmzehcwluk (qnyrnrbvur, ciwernzbfb - rhergdhliz) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free